Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.

Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

These stories from the past year show how Vanderbilt is making an impact, on campus and in the world.

Vanderbilt University’s Craig Lindsley, Ph.D., is the 2013 recipient of the Philip S. Portoghese Lectureship, awarded jointly by the Journal of Medicinal Chemistry and the American Chemical Society (ACS) Division of Medicinal Chemistry.

Vanderbilt University’s Lee Limbird, Ph.D., has received one of pharmacology’s highest honors — the 2013 Julius Axelrod Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET).